GlassScriptPhysician profile
Thuan V Pham
NPI 1144330218
$10,737.10
in general payments reported to CMS, 2019-2025
55 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $823 · 2021: $1,613 · 2022: $2,356 · 2023: $1,091 · 2024: $1,360 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,277.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.14 | 2019-2025 | |
| Pfizer INC. | $962.71 | 2019-2025 | |
| Lilly USA, LLC | $927.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $902.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $831.16 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $687.33 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.11 | 2019-2025 | Jardiance, Spiriva Respimat, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $573.03 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astellas Pharma US INC | $436.65 | 2020-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $314.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.83 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $268.45 | 2019-2021 | |
| Amgen INC. | $198.39 | 2019-2025 | Otezla, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $182.80 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $178.00 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.